Literature DB >> 26101567

Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.

Peter G M Wuts1, Lloyd J Simons1, Brian P Metzger2, Rachel C Sterling2, Jerry L Slightom2, Ake P Elhammer2.   

Abstract

The natural product aureobasidin A (AbA) is a potent, well-tolerated antifungal agent with robust efficacy in animals. Although native AbA is active against a number of fungi, it has little activity against Aspergillus fumigatus, an important human pathogen, and attempts to improve the activity against this organism by structural modifications have to date involved chemistries too complex for continued development. This report describes novel chemistry for the modification of AbA. The key step involves functionalization of the phenylalanine residues in the compound by iridium-catalyzed borylation. This is followed by displacement of the pinacol boron moiety to form the corresponding bromide or iodide and substitution by Suzuki biaryl coupling. The approach allows for synthesis of a truly wide range of derivatives and has produced compounds with A. fumigatus minimal inhibitory concentrations (MIC) of <0.5 μg/mL. The approach is readily adaptable to large-scale synthesis and industrial production.

Entities:  

Keywords:  C−H borylation; SAR; antifungal; aureobasidin A

Year:  2015        PMID: 26101567      PMCID: PMC4468416          DOI: 10.1021/acsmedchemlett.5b00029

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Aureobasidins as new inhibitors of P-glycoprotein in multidrug resistant tumor cells.

Authors:  T Kurome; K Takesako; I Kato
Journal:  J Antibiot (Tokyo)       Date:  1998-03       Impact factor: 2.649

2.  Role of ABC transporters in aureobasidin A resistance.

Authors:  A Ogawa; T Hashida-Okado; M Endo; H Yoshioka; T Tsuruo; K Takesako; I Kato
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Unique molecular conformation of aureobasidin A, a highly amide N-methylated cyclic depsipeptide with potent antifungal activity: X-ray crystal structure and molecular modeling studies.

Authors:  Y In; T Ishida; K Takesako
Journal:  J Pept Res       Date:  1999-05

4.  Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.

Authors:  F Tiberghien; T Kurome; K Takesako; A Didier; T Wenandy; F Loor
Journal:  J Med Chem       Date:  2000-06-29       Impact factor: 7.446

5.  Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins.

Authors:  K Kino; Y Taguchi; K Yamada; T Komano; K Ueda
Journal:  FEBS Lett       Date:  1996-12-09       Impact factor: 4.124

6.  Inositol phosphorylceramide synthase is located in the Golgi apparatus of Saccharomyces cerevisiae.

Authors:  T P Levine; C A Wiggins; S Munro
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

Review 7.  Recent progress in the chemotherapy of human fungal diseases. Emphasis on 1,3-β-glucan synthase and chitin synthase inhibitors.

Authors:  Anwer Basha; Fatima Basha; Syed Kashif Ali; Paul R Hanson; Lester A Mitscher; Berl R Oakley
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 8.  Predicting ligand interactions with ABC transporters in ADME.

Authors:  Michael A Demel; O Krämer; Peter Ettmayer; Eric E J Haaksma; Gerhard F Ecker
Journal:  Chem Biodivers       Date:  2009-11       Impact factor: 2.408

9.  Effect of membrane perturbants on the activity and phase distribution of inositol phosphorylceramide synthase; development of a novel assay.

Authors:  Paul A Aeed; Andrea E Sperry; Casey L Young; Marek M Nagiec; Ake P Elhammer
Journal:  Biochemistry       Date:  2004-07-06       Impact factor: 3.162

10.  The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337).

Authors:  S A Heidler; J A Radding
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  4 in total

Review 1.  Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections.

Authors:  Cheng Zhen; Hui Lu; Yuanying Jiang
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

Review 2.  Sphingolipids as targets for treatment of fungal infections.

Authors:  Rodrigo Rollin-Pinheiro; Ashutosh Singh; Eliana Barreto-Bergter; Maurizio Del Poeta
Journal:  Future Med Chem       Date:  2016-08-09       Impact factor: 3.808

3.  The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis.

Authors:  A Q I Alqaisi; A J Mbekeani; M Bassas Llorens; A P Elhammer; P W Denny
Journal:  Parasitology       Date:  2017-05-10       Impact factor: 3.234

Review 4.  Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.

Authors:  John G M Mina; P W Denny
Journal:  Parasitology       Date:  2017-06-22       Impact factor: 3.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.